Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension

European Respiratory Journal

Volumn 33, Issue 6, 2009, Pages 1354-1360

  Jing, Z C ^a   Jiang, X ^a   Han, Z Y ^b   Xu, X Q ^c   Wang, Y ^d   Wu, Y ^b   Lv, H ^e   Ma, C R ^a   Yang, Y J ^b   Pu, J L ^b  

^a TONGJI UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

^c Aviation Industry Central Hospital   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Beijing Command College of Chinese People's Armed Police Force   (China)

Author keywords

Adenosine; Calcium channel blockers; Iloprost; Inhaled therapy; Pulmonary arterial hypertension; Vasoreactivity testing

Indexed keywords

ADENOSINE; DILTIAZEM; ILOPROST;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AEROSOL; AGED; ARTICLE; CHILD; CLINICAL EVALUATION; CONSENSUS; CONTROLLED STUDY; COUGHING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUSHING; FOLLOW UP; HEART CATHETERIZATION; HEART INDEX; HEART PALPITATION; HEMODYNAMIC PARAMETERS; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SIDE EFFECT; SORE THROAT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VASODILATATION;

ADENOSINE; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; AGED; CALCIUM CHANNEL BLOCKERS; CHILD; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; VASODILATOR AGENTS;

EID: 69249119028     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00169608     Document Type: Article

References (25)

1. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
2. Groves BM, Badesch DB, Turkevich D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir KE, Hume JR, Reeves JT, eds. Ion Flux in Pulmonary Vascular Control. New York, Plenum, 1993; pp. 317-330.
3. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 35S-62S.
4. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension.The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
5. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365.
6. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
7. Schrader BJ, Inbar S, Kaufmann L, et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 19: 1060-1064.
8. Ricciardi MJ, Knight BP, Martinez FJ, et al. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32: 1068-1073.
9. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.
10. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 56S-61S.
11. Fullerton DA, Kirson LE, Jones SD, et al. Adenosine is a selective pulmonary vasodilator in cardiac surgical patients. Chest 1996; 109: 41-46.
12. Miller OI, Tang SF, Keech A, et al. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346: 51-52.
13. Lavoie A, Hall JB, Olson DM, et al. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1996; 153: 1985-1987.
14. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000; 35: 176-182.
15. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891-901.
16. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552.
17. Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32: 73-97.
18. Goldsmith DR, Wagstaff AJ. Inhaled iloprost: in primary pulmonary hypertension. Drugs 2004; 64: 763-773.
19. Palevsky HI, Long W, Crow J, et al. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990; 82: 2018-2026.
20. Galiè N, Ussia G, Passarelli P, et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55A-62A.
21. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
22. Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure, morphometry and responsiveness to vasodilator agents. Circulation 1989; 80: 1207-1221.
23. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484-488.
24. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-469.
25. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.